Effect of Bydureon on Carotid Atherosclerosis Progression in T2DM
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 21 Jun 2018
Price : $35 *
At a glance
- Drugs Exenatide (Primary)
- Indications Atherosclerosis; Type 2 diabetes mellitus
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 12 Jun 2018 Status changed from recruiting to active, no longer recruiting.
- 12 Jun 2018 Planned End Date changed from 1 Jun 2018 to 1 Sep 2019.